Additional Information
Market: AIM / ASX
Sector: General Mining - Gold
EPIC: NGL
Latest Price: 3.75p  (2.46% Ascending)
52-week High: 29.75p
52-week Low: 3.10p
Market Cap: 15.31M
1 year chart
1 day chart
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Norseman Gold
www.norsemangold.com

Norseman Gold plc is an AIM and ASX listed gold production and exploration company. Its key asset is the Norseman Project, which lies at the southern extent of the Norseman-Wiluna Greenstone Belt in the Eastern Gold fi elds Province of the Yilgarn Block, Western Australia. The Norseman Project is operated and managed by resource specialist, Tulla Resources Group Pty Ltd, which is focussed on producing 100,000 ounces of gold per annum by 2014 and increasing the resource base, currently standing at 3.4 million ounces of gold at an average grade of 4.7g/t.  A review of operations is currently underway aimed at maximising future production and reducing costs.

Pdf

Norseman Gold undervalued as it is set to double production this year, says broker

6th Sep 2011, 4:37 pm by Jon Mainwaring Seymour Pierce used 'conservative' gold price estimates to come up with its forecasts

In spite of a more conservative view of potential production by both management and Seymour Pierce, Australia-focused Norseman Gold (LON:NGL, ASX: NGX) will double production this year according to the house broker.

Seymour Pierce said in a research note today that last week’s results for Norseman’s 2011 financial year showed the firm’s loss – A$12.2 million at the pre-tax level – as being a little lighter than it had expected, while it noted that production guidance for 2012 of in excess of 100,000 ounces had been reiterated.

The broker said that, as flagged in its recent notes, it had been expecting the need to downgrade its forecasts once the dust had settled on a turbulent 2011. Its 2012 and 2013 production expectations have now been lowered to match the company’s comments and it assumes 100,000 ounces and 105,000 ounces for 2012 and 2013.

“However, this still means a doubling of production this year. Norseman remains one of the lowest rated gold plays around, so successfully executing the new production plan should bring further improvements in the share price,” said Seymour Pierce.

Last year, Norseman’s gold sales of 50,200 ounces at an average price of A$1,374 per ounce and average operating costs of A$1,227 per ounce resulted in a pre-tax loss of A$12.2 million and an adjusted loss per share of 3.4 cents. During the year more than A$40 million was invested in mine development, property, plant and equipment and reduced exploration programme.

Net debt stood at A$4.3 million at the year end, but Seymour Pierce noted that the firm subsequently secured an A$15 million working capital facility that “should prove sufficient if production increases as expected”.

According to the broker, the other item of note in Norseman’s accounts is an A$15 million goodwill impairment charge the company has made to reflect a more modest production outlook over the next five years. “Average annual output is now assumed at 100,000 to 110,000 ounces against the previous 130,000 to 140,000 level – a sensible approach in our view given the recent experiences on site,” it said, pointing out that the highlight in terms of operational outlook is the expectation of first commercial production from the North Royal pit in Q2 2012.

Since Seymour Pierce has lowered its production expectations to match the company’s comments, it has also used conservative gold price assumptions (US$1,450 per ounce for 2012 and US1,325 per ounce for 2013) as well as conservative cost estimates to come up with earnings per share estimates for 2012 and 2013 of 2.9 cents and 7.2 cents respectively. “Current gold prices imply earnings at least twice as high though,” said the broker, which is maintaining its 52 pence per share resource-based valuation in the short term.

Shares in Norseman closed down 0.75 pence at 25.5 pence each today.


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.